Benzodiazepines Screen With Reflex Confirmation, Whole Blood
Use
This test is designed to screen for the presence of benzodiazepines in whole blood samples. Benzodiazepines are a class of psychoactive drugs that have a range of uses including treatment of anxiety, insomnia, seizures, and other conditions. Screening for benzodiazepines is crucial in clinical toxicology to assess compliance with prescribed medications and detect possible medication misuse or drug abuse.
Special Instructions
For samples requiring storage beyond three days, ensure refrigeration or freezing to maintain specimen integrity. Follow proper specimen collection procedures using the appropriate container as indicated. This test is not FDA-approved, and its performance characteristics have been determined by the testing laboratory.
Limitations
The test uses a presumptive immunoassay method, which may give false-positive results due to cross-reactivity with other substances. Confirmatory testing is done using chromatography mass spectrometry for more accurate results. However, this test is not FDA cleared, and results should be interpreted in the context of the patient's clinical condition and history.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 42662-7
- 42662-7
Result Turnaround Time
4-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
7 mL
Minimum Volume
3 mL
Container
Gray-top (sodium fluoride/potassium oxalate) tube, green-top (heparin) tube, or lavender-top (EDTA) tube
Storage Instructions
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.